GlycoVaxyn's proprietary technology enables the development and production of immunogenic glycoproteins (polysaccharide and protein complexes) for use in conjugated vaccines, in a simplified process that significantly reduces costs and many of the steps involved in current methods for producing vaccines. As a result, GlycoVaxyn is able to target bacterial diseases for which effective and/or affordable vaccines do not currently exist.
GlycoVaxyn is developing a pipeline of bioconjugate vaccine candidates that target some of the most common and severe bacterial infections that occur in childhood and throughout life. Its lead vaccines target the main bacterial pathogens that cause travelers' diarrhea. Longer term, GlycoVaxyn will adapt its technology to create cancer vaccines and therapeutic glycoproteins.
GlycoVaxyn was founded in 2004 as a spin-out company from the Swiss Federal Institute of Technology (ETH) to commercialize the glycoprotein technology developed by its scientific founder. GlycoVaxyn is based in Schlieren, near Zurich, Switzerland, and announced the successful closing of a CHF 25 million (approx. US$ 22 million, € 17 million) series B financing. The round was led by Edmond de Rothschild Investment Partners. Existing investors, Index Ventures and Sofinnova Partners, expressed their commitment to the future of the company through significant participation in this round.
